Pablo D. L. C.
- Country
- Spain
- Department
- Dermatology
Research Overview
- Evaluation of Amlitelimab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis with Topical Corticosteroids: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
Data & Insights
Has run more than one trial at 3 of 105 partner sites.
Specializations
Dermatological Research
The investigator specializes in the treatment of atopic dermatitis, with particular focus on evaluating novel therapeutic approaches for moderate to severe cases.
- Advanced treatment modalities for atopic conditions
- Therapeutic dose optimization
- Long-term disease management strategies
Their research encompasses innovative treatment protocols involving targeted immunological interventions.
Therapeutic Innovation
The investigator conducts research on biological therapies including assessment of novel compounds like upadacitinib and lebrikizumab for dermatological conditions.
- Dose flexibility assessment
- Treatment response evaluation
- Safety profile analysis
Their work includes evaluation of variable dosing regimens and long-term effectiveness of treatments.
Clinical Assessment
The investigator focuses on measuring therapeutic outcomes using standardized assessment tools such as the Eczema Area and Severity Index.
- Disease severity monitoring
- Clinical response assessment
- Sustained improvement evaluation
Their research encompasses both adult and adolescent patient populations in clinical studies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.